

## Gyne 2-23: Schwerpunkte:

### Schwerpunkt: Hormone

*Titel: Hormonersatztherapie (HRT) zum Schutz der Lungenfunktion und vor Lungenkrebs (S. 8-12)*

*Autor: J.M. Wenderlein*

### Literatur:

1. Triebner K et al. Menopause is associated with accelerated lung function decline. *Am J Respir Crit Care Med* 2017;195:1058-65
2. Klingberg S et al. Loss of height predicts total and cardiovascular mortality: a cohort study of northern European women. *BMJ Open* 2021;11:e049122; <https://doi.org/10.1136/bmjopen-2021-049122>
3. Wang YX et al. Menstrual cycle regularity and length across the reproductive lifespan and risk of preterm mortality: prospective cohort study. *BMJ* 2020;371:m3464
4. Amaral AF et al. Lower lung function associates with cessation of menstruation: UK Biobank data. *Eur Respir J* 2016;48(5):1288-97
5. Whitcomb BW et al. Cigarette smoking and risk of early natural menopause. *Am J Epidemiol* 2018;187:696-704
6. Campbell B et al. Menopausal lung function and obstructive lung disease outcomes: a systematic review. *Climacteric* 2017;19:13689-7137
7. Real FG. Lung function, respiratory symptoms, and the menopausal transition. *J Allergy Clin Immunol* 2008;121:72-80
8. Bonneleykke K et al. Postmenopausal hormone therapy and asthma-related hospital admissions. *J ALLERGY Allergy Clin Immunol* 2013;135(3):813-15
9. Cevrioglu AS et al. The effects of hormone therapy on pulmonary function tests in postmenopausal women. *Maturitas* 2004;49:221-7
10. Elliott AM & Hannaford PC. Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. *Contraception* 2006;73(4):331-5
11. Kreuzer M et al. Hormonal factors and risk of lung cancer among women? *Int J Epidemiol* 2003;32(2):263-71
12. Yao Y et al. Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis. *PLoS ONE* 2013;8(8):e71236
13. Clague, J et al. Menopausal hormone therapy does not influence lung cancer risk: results from the California Teachers Study. *Cancer Epidemiol Biomarkers Prev* 2011;20(3):560-4
14. Wu W et al. Association of oral contraceptives use and lung cancer risk among women: an updated meta-analysis based on cohort and case-control studies. *Asian Pac J Cancer Prev* 2014;15(3):1205-10
15. Pesatori AC et al. Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO). *Br J Cancer* 2013;109(7):1954-64
16. Titan AL et al. The influence of hormone replacement therapy on lung cancer incidence and mortality. *J Thorac Cardiovasc Surg* 2020;159(4):1546-56
17. Abdel-Rahman O et al. Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis. *Int J Clin Oncol* 2020;25(5):885-91
18. Mikkola TS et al. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. *Menopause* 2016;23(11):1199-1203
19. Musial C et al. Plausible Role of Estrogens in Pathogenesis, Progression and Therapy of Lung Cancer 2021;18(2):648

20. Vachani A et al. The probability of lung cancer in patients with incidentally detected pulmonary nodules: clinical characteristics and accuracy of prediction models. *Chest* 2021;161(2):562–71

### **Schwerpunkt: Gynäkologische Onkologie**

*Titel: Welchen Nutzen haben Biofaktoren in der komplementären Onkologie? (S.16-19)*

*Autor: D. Birkelbach*

### **Literatur:**

1. <https://www.dge.de/wissenschaft/referenzwerte/?L=0>
2. Informationen zu Mangelsymptomatik und Labordiagnostik wichtiger Biofaktoren: [www.gf-biofaktoren.de](http://www.gf-biofaktoren.de)
3. Mohn et al. Evidence of Drug-Nutrient interactions with chronic use of commonly prescribed medications: An update. *Pharmaceutics* 2018;10(1):36
4. Samaras D et al. Effects of widely used drugs on micronutrients: A story rarely told. *Nutrition* 2013; 29(4):605-10
5. Gröber U. Arzneimittel und Mikronährstoffe. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH 2007
6. Keum N et al. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. *Ann Oncol* 2019;30(5):733-43
7. Haykal T et al. The role of vitamin D supplementation for primary prevention of cancer: meta-analysis of randomized controlled trials. *J Community Hosp Intern Med Perspect* 2019;9(6):480-8
8. Zhang X et al. Meta-analysis of randomized controlled trials on vitamin D supplement and cancer incidence and mortality. *Biosci Rep* 2019;39(11):BSR20190369
9. Maalmi H et al. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: Systematic review and meta-analysis of prospective cohort studies. *Eur J Cancer* 2014; 50(8):1510-21
10. Sutherland JP et al. Vitamin D Deficiency increases mortality risk in the OK Biobank. *Annals of Internal Medicine* 2022;175(11):1552-9
11. Manson KE et al. Principal results of the VITamin D and Omega-3 Trial (VITAL) and updated meta-analyses of relevant vitamin D trials. *J Steroid Biochem Mol Biol* 2020;198:105522
12. Ma Y et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. *Sci Transl Med* 2014;6(222):222ra18
13. Creagan ET et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. *N Engl J Med* 1979;301(13):687-90
14. Moertel CG et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. *N Engl J Med* 1985;312(3):137-41
15. Jacobs C et al. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. *Oncologist* 2015;20(2):210-23
16. <https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/>
17. Ohno S et al. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. *Cancer Res* 2009;29(3):809-15
18. Nauman G et al. Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. *Antioxidants (Basel)* 2018;7(7):89
19. Mohseni S et al. Effect of vitamins C and E on cancer survival; a systematic review. *Daru* 2022; 30(2):427-41
20. Fritz H et al. Intravenous Vitamin C and Cancer: A Systematic Review. *Integr Cancer Ther* 2014;13(4):280-300

21. Prasad AS et al. Zinc in cancer prevention. *Nutr Cancer* 2009;61(6):879-87
22. Gelbard A. Zinc in cancer therapy revisited. *Isr Med Assoc J* 2022;24(4):258-62
23. Choi S et al. Selective inhibitory effects of zinc on cell proliferation in esophageal squamous cell carcinoma through Orai1. *FASEB J* 2018;32(1):404-16
24. Kwak JH et al. Dietary zinc intake and mortality in patients with intestinal-type gastric cancer: A prospective cohort study in Korea. *Front Oncol* 2022;12:947405
25. Hoppe C et al. Zinc as a complementary treatment for cancer patients: a systematic review. *Clinical and Experimental Medicine* 2021;21:297–313

### **Schwerpunkt: Korasion**

*Titel: Fertilitätserhalt bei onkologischen Erkrankungen im Kindes- und Jugendalter (S.20-24)*

*Autor: L. Lotz, R. Dittrich*

### **Literatur:**

1. Lotz L et al. The safety and satisfaction of ovarian tissue cryopreservation in prepubertal and adolescent girls. *Reprod Biomed Online* 2020;40(4):547-54
2. S2k-Leitlinie, Fertilitätserhalt bei onkologischen Erkrankungen (AWMF Register-No. 015/082) <http://www.awmf.org/leitlinien/detail/II/015-082.html>, 2017.
3. Cobo A et al. Oocyte vitrification for fertility preservation for both medical and nonmedical reasons. *Fertil Steril* 2021;115(5):1091-101
4. Khattak H et al. Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis. *Human Reproduction Update* 2022;28(3):400-16
5. Lotz L et al. Determinants of transplantation success with cryopreserved ovarian tissue: data from 196 women of the FertiPROTEKT network. *Human Reproduction* 2022
6. Demeestere I et al. Live birth after autograft of ovarian tissue cryopreserved during childhood. *Human Reproduction* 2015;30(9):2107-9
7. Matthews SJ et al. Successful pregnancy in a woman previously suffering from  $\beta$ -thalassemia following transplantation of ovarian tissue cryopreserved before puberty. *Minerva Ginecol* 2018;70(4):432-35
8. Dolmans MM et al. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. *Fertil Steril* 2013;99(6):1514-22
9. Dolmans MM et al. Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers. *Fertil Steril* 2021;115(5):1102-15
10. Raffel N et al. Novel approach for the assessment of ovarian follicles infiltration in polymeric electrospun patterned scaffolds. *PLoS One* 2019;14(4):e0215985
11. Preservation T.E.G.G.o.F.F et al. ESHRE guideline: female fertility preservation†. *Human Reproduction Open* 2020;2020(4)
12. Barahmeh S et al. Ovarian transposition before pelvic irradiation: indications and functional outcome. *J Obstet Gynaecol Res* 2013;39(11):1533-7
13. Hoekman EJ et al. Ovarian function after ovarian transposition and additional pelvic radiotherapy: A systematic review. *Eur J Surg Oncol* 2019;45(8):1328-40
14. Gubbala K et al. Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis. *J Ovarian Res* 2014;7:69
15. Sanger N and Barnbrock A. Fertilitatserhalt bei Kindern. *Der Gynekologe* 2019;52(11):868-72
16. Sanger N and Allam JP. Kinderwunsch trotz onkologischer Therapie: Sofort nach der Diagnose die Fruchtbarkeit sichern. *Dtsch Arztebl International* 2022;119(7):6
17. Kanbar M et al Fertility preservation for prepubertal boys: are we ready for autologous grafting of cryopreserved immature testicular tissue? *Ann Endocrinol (Paris)* 2022;83(3):210-17

18. Arapaki A et al. Ovarian Tissue Cryopreservation in Children and Adolescents. *Children (Basel)* 2022;9(8)
19. Rodriguez-Wallberg KA et al. Fertility preservation for young adults, adolescents, and children with cancer. *Ups J Med Sci* 2020;125(2):112-20

### **Schwerpunkt: Gynäkologische Onkologie**

*Titel: Aktuelles zum gesetzlichen Früherkennungsprogramm des Zervixkarzinoms in Deutschland (S.25-32)*

*Autor: A. Behrens, M.W. Beckmann, F.A. Stübs*

### **Literatur:**

1. Zentrum für Krebsregisterdaten, Robert Koch-Institut. Krebs in Deutschland. Gebärmutterhalskrebs (Zervixkarzinom). ICD-10 C53 ([https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs\\_in\\_Deutschland/kid\\_2021/kid\\_2021\\_c53\\_gebaermutterhals.pdf?\\_\\_blob=publicationFile](https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2021/kid_2021_c53_gebaermutterhals.pdf?__blob=publicationFile)). Zugriffen: 31.10.2022.
2. Schiffman M et al. Human papillomavirus and cervical cancer. *Lancet* 2007;370:890–907
3. Robert Koch-Institut. Empfehlungen der Ständigen Impf-kommission (STIKO) beim Robert Koch-Institut 2022. Epi-demio-logisches Bulletin 2022
4. Stübs FA et al. HPV-Diagnostik und Therapie in der Prävention. *Frauenheilkunde up2date* 2021;15:537–49
5. Stübs FA et al. Krebsfrüherkennung des weiblichen Genitales. *Frauenheilkunde up2date* 2018; 12: 519–29
6. Schulmeyer CE et al. Gynäkologische Krebsfrüherkennung des Zervixkarzinoms im Wandel der Zeit. *Gyn Praktische Gynäkologie* 2017:386–98
7. Stuebs FA et al. Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix. *Arch Gynecol Obstet* 2021;304:751–8
8. Bosch FX et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. *J Natl Cancer Inst* 1995;87:796–802
9. Gemeinsamer Bundesausschuss. Richtlinie des Ge-mein-samen Bundesausschusses für organisierte Krebs-früh-er-ken-nungsprogramme oKFE-Richtlinie/oKFE-RL. (<https://www.g-ba.de/downloads/62-492-2605/oKFE-RL-2021-07-01-iK-2022-01-01.pdf>). Zugriffen: 02.11.2022
10. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Prävention des Zervixkarzinoms. Langversion 1.1. 2020. AWMF-Registernummer: 015/027OL. (<https://www.awmf.org/leitlinien/detail/II/015-027OL.html>). Zugriffen: 02.11.2022
11. Institut für Qualität und Wirtschaftlichkeit im Gesund-heits-wesen (IQWiG). Nutzenbewertung eines HPV-Tests im Primär-screening des Zervixkarzinoms: Abschlussbericht. Auftrag: S10-01. Version: 1.0. Stand: 28.11.2011. ([https://www.iqwig.de/download/s10-01\\_ab\\_hpv-test\\_im\\_primaerscreening\\_des\\_zervixkarzinoms.pdf](https://www.iqwig.de/download/s10-01_ab_hpv-test_im_primaerscreening_des_zervixkarzinoms.pdf)). Zugriffen: 02.11.2022.
12. Hillemanns P et al. Statement of the AGO and AG-CPC on the Aftercare/Follow-up for Surgical Procedures of the Lower Genital Tract after the Introduction of a New Cancer Screening Guideline. *Geburtshilfe Frauenheilkd* 2020;80:809–12
13. Stuebs FA et al. Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment. *Diagnostics (Basel)* 2022;12:1748

14. Karimi-Zarchi M et al. A Comparison of 3 Ways of Conventional Pap Smear, Liquid-Based Cytology and Colposcopy vs Cervical Biopsy for Early Diagnosis of Premalignant Lesions or Cervical Cancer in Women with Abnormal Conventional Pap Test. *Int J Biomed Sci* 2013;9:205–10
15. Müller K et al. Accuracy of Colposcopically Guided Diagnostic Methods for the Detection of Cervical Intraepithelial Neoplasia. *Geburtshilfe Frauenheilkd* 2016;76:182–7
16. Marquardt K et al. An der Schwelle zum organisierten Zervixkarzinomscreening. Befunde der Münchner Nomenklatur III und zytologisch-histologische Korrelation. *Gynakologe* 2019;52:622–7
17. Marquardt K et al. Risiko-be-wer-tung von Zytologiebefunden im Zervixkarzinom-Screening. *Gynakologe* 2019;52:937–44
18. Beckmann MW et al. Establishment of the Certification System „Gynaecological Dysplasia“ in Germany. *Geburtshilfe Frauenheilkd* 2014;74:860–7
19. Arbeitsgemeinschaft Zervixpathologie und Kolposkopie e. V. Dysplasieportal. (<https://www.dysplasieportal.de/>). Zugegriffen: 14.08.2022.
20. Deutsche Krebsgesellschaft. OncoMap.(<https://www.oncomap.de/cnetworks/cnoncos?selectedCounty=Deutschland&selectedCerttype=DKG>). Zugegriffen: 14.08.2022
21. Lei J et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. *N Engl J Med* 2020;383:1340–8
22. Garland SM. The Australian experience with the human papillomavirus vaccine. *Clin Ther* 2014;36:17–23
23. Munoz N et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. *Lancet* 2009;373:1949–57
24. Olsson S-E et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. *Hum Vaccin* 2009;5:696–704
25. Schwarz TF et al.; HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. *Vaccine* 2009;27:581–7
26. Castellsagué X et al. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. *Gynecol Oncol* 2009;115 (Suppl):15–23
27. Harper DM et al. HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* 2006;367:1247–55
28. Kang WD et al. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? *Gynecol Oncol* 2013;130:264–8
29. Lichter K et al. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. *Obstet Gynecol* 2020;135:1070–83
30. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Evidenz- und konsensbasierte Leitlinie. Impfprävention HPV-assoziierter Neoplasien. Lang-version 1.1. 2020. AWMF-Registernummer: 082-002 ([https://www.awmf.org/uploads/tx\\_szleitlinien/082-002l\\_S3\\_Impfpraevention-HPV-assoziierter-Neoplasien\\_2020-07\\_01.pdf](https://www.awmf.org/uploads/tx_szleitlinien/082-002l_S3_Impfpraevention-HPV-assoziierter-Neoplasien_2020-07_01.pdf)). Zugegriffen: 02.11.2022
31. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom. Langversion 2.2. 2022

**Schwerpunkt: Pharmaservice**

*Titel: Thromboembolie-Risiko: „Ein orales Gestagen-Monopräparat geht fast immer“ (S.40)*

*Autor: Ronny Reimann*

**Literatur:**

1. Statistisches Bundesamt Deutschland 2020
2. Palacios S et al. A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg. Arch Gynecol Obstet 2019;300(6):1805–12
3. Archer DF et al. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception 2015;92(5):439–44
4. Palacios S et al. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand 2019; 98(12): 1549–57
5. Melka D et al. A single-arm study to evaluate the transfer of drospirenone to breast milk after reaching steady state, following oral administration of 4 mg drospirenone in healthy lactating female volunteers. Womens Health (Lond) 2020;16:1745506520957192
6. S3-Leitlinie Hormonelle Empfängnisverhütung

**Schwerpunkt: Pharmaservice**

*Titel: Impfen in der gynäkologischen Praxis (S.40)*

*Autor: Ronny Reimann*

**Literatur:**

1. Mbayei SA et al. Severe Pertussis Infections in the United States, 2011-2015. CID 2019;69(2):218–26
2. Epidemiologisches Bulletin 4/2023:23